{"name":"Nykode Therapeutics ASA","slug":"nykode-therapeutics-asa","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Atezolizumab Injection [Tecentriq]","genericName":"Atezolizumab Injection [Tecentriq]","slug":"atezolizumab-injection-tecentriq","indication":"Metastatic non-small cell lung cancer (NSCLC)","status":"marketed"}]}],"pipeline":[{"name":"Atezolizumab Injection [Tecentriq]","genericName":"Atezolizumab Injection [Tecentriq]","slug":"atezolizumab-injection-tecentriq","phase":"marketed","mechanism":"Atezolizumab is a monoclonal antibody that blocks PD-L1 on tumor and immune cells, releasing the brakes on T-cell-mediated anti-tumor immunity.","indications":["Metastatic non-small cell lung cancer (NSCLC)","Metastatic urothelial carcinoma","Small cell lung cancer (SCLC)","Hepatocellular carcinoma","Breast cancer (triple-negative)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}